Rhythm Pharmaceuticals amends LG Chem license and announces $750 million financing
FROM THE WIRE · FINANCE.YAHOO.COM
Rhythm Pharmaceuticals (NasdaqGM:RYTM) amended its global license deal with LG Chem covering obesity candidate bivamelagon. The revised agreement alters long term royalty terms for bivamelagon as Rhythm refines economics on its MC4R portfolio. Management also announced a new…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA $750 million financing for a specialist biotech is relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Rhythm amended its global license with LG Chem on bivamelagon.
- 02Long-term royalty terms for bivamelagon were revised.
- 03The company announced a new $750 million financing package.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets